Valuation: Endonovo Therapeutics, Inc.

Market Cap 2.77M 2.43M 2.24M 2.09M 3.94M 262M 4.03M 26.98M 10.41M 129M 10.41M 10.19M 449M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.69M 8.02M 7.49M 14.1M 938M 14.43M 96.56M 37.28M 463M 37.28M 36.46M 1.61B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 70 01/03/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
-9.62%-18.42% - - 1.81K
+3.18%-0.32%+72.50%+128.02% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
+3.33%+4.51%-11.68%-11.91% 23.84B
+1.32%+6.22%+5.28%+415.45% 22.7B
+7.08%+7.78%+40.04%-28.62% 16.12B
-0.89%+5.71%+24.30%+186.29% 13.64B
+9.96%+15.98%+157.65%+310.89% 14.8B
+2.85%+2.81%+75.32%+139.44% 12.16B
+6.17%+10.22%+163.15%+166.44% 11.85B
Average +3.01%+7.40%+68.69%+156.68% 25.17B
Weighted average by Cap. +4.50%+7.70%+66.85%+143.15%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.06 0.1 6.91 0.11 0.71 0.27 3.41 0.27 0.27 11.84 0.14 0.12 0.11 0.1 0.19 12.8 0.2 1.32 0.51 6.31 0.51 0.5 21.92
Net income -3.1M -2.72M -2.51M -2.34M -4.41M -294M -4.51M -30.2M -11.66M -145M -11.66M -11.4M -503M -18.47M -16.18M -14.93M -13.95M -26.25M -1.75B -26.85M -180M -69.38M -862M -69.38M -67.86M -2.99B
Net Debt 7.1M 6.21M 5.74M 5.36M 10.08M 671M 10.31M 69.02M 26.64M 331M 26.65M 26.06M 1.15B 7.15M 6.26M 5.78M 5.4M 10.16M 676M 10.4M 69.58M 26.86M 334M 26.86M 26.27M 1.16B
Logo Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-